Today, I have another controversial prediction. One which I will take no pleasure in seeing come true. See, even with President Trump returning as the leader of our free country, I believe Elon Musk is in mortal danger.

I share with you in this special investigative documentary.

Christopher J. Tovey net worth and biography

Christopher Tovey Biography and Net Worth

COO of Jazz Pharmaceuticals

Chris Tovey was appointed executive vice president, chief operating officer and managing director of Europe & International in May 2021 following the acquisition of GW Pharmaceuticals, where he served as executive vice president and chief operating officer since joining the company in 2012 and as a board director until 2017. He brings over 30 years of commercial leadership and operations experience in the pharmaceutical industry to his role, where he oversees all Jazz commercial activities outside of North America, as well as global manufacturing and supply chain, and information technology and security. Mr. Tovey’s passion for patients fuels his enthusiasm and drive to find new and better ways to serve them, including work to develop and commercialize world-first breakthrough medicines.

What is Christopher J. Tovey's net worth?: The estimated net worth of Christopher J. Tovey is at least $1.80 million as of July 5th, 2022. Mr. Tovey owns 14,663 shares of Jazz Pharmaceuticals stock worth more than $1,803,109 as of December 21st. This net worth evaluation does not reflect any other investments that Mr. Tovey may own. Learn More about Christopher J. Tovey's net worth.
How do I contact Christopher J. Tovey?: The corporate mailing address for Mr. Tovey and other Jazz Pharmaceuticals executives is FIFTH FLOOR WATERLOO EXCHANGE WATERLOO ROAD, DUBLIN L2, D04. Jazz Pharmaceuticals can also be reached via phone at (531) 634-7800 and via email at [email protected]. Learn More on Christopher J. Tovey's contact information.
Has Christopher J. Tovey been buying or selling shares of Jazz Pharmaceuticals?: Christopher J. Tovey has not been actively trading shares of Jazz Pharmaceuticals during the last quarter. Most recently, Christopher J. Tovey sold 5,209 shares of the business's stock in a transaction on Tuesday, July 5th. The shares were sold at an average price of $160.00, for a transaction totalling $833,440.00. Following the completion of the sale, the chief operating officer now directly owns 14,663 shares of the company's stock, valued at $2,346,080. Learn More on Christopher J. Tovey's trading history.
Who are Jazz Pharmaceuticals' active insiders?: Jazz Pharmaceuticals' insider roster includes Paul Berns (Director), Patricia Carr (SVP), Jennifer Cook (Director), Bruce Cozadd (Co-Founder, Chairman & CEO), Patrick Enright (Director), Renée Galá (CFO), Peter Gray (Director), Mary Henderson (SVP, Technical Operations), Robert Iannone (EVP), Philip Johnson (CFO), Finbar Larkin (SVP), Seamus Mulligan (Director), Kenneth O'Keefe (Director), Anne Oriordan (Director), Neena Patil (Insider), Samantha Pearce (SVP), Kim Sablich (EVP), Elmar Schnee (Director), Mark Smith (Director), Christopher Tovey (COO), and Rick Winningham (Director). Learn More on Jazz Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Jazz Pharmaceuticals?: During the last year, Jazz Pharmaceuticals insiders bought shares 1 times. They purchased a total of 12,000 shares worth more than $1,435,800.00. During the last year, insiders at the specialty pharmaceutical company sold shares 8 times. They sold a total of 15,262 shares worth more than $1,766,604.30. The most recent insider tranaction occured on December, 2nd when CEO Bruce C Cozadd sold 2,000 shares worth more than $242,340.00. Insiders at Jazz Pharmaceuticals own 4.2% of the company. Learn More about insider trades at Jazz Pharmaceuticals.
Information on this page was last updated on 12/2/2024.

Christopher J. Tovey Insider Trading History at Jazz Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
7/5/2022	Sell	5,209	$160.00	$833,440.00	14,663

Christopher J. Tovey Buying and Selling Activity at Jazz Pharmaceuticals

Jazz Pharmaceuticals Company Overview

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson's disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders. The company has licensing and collaboration agreements with XL-protein GmbH to extend the plasma half-life of selected asparaginase product candidates; Redx Pharma plc for preclinical activities Ras/Raf/MAP kinase pathway program; and Autifony Therapeutics Limited on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.

Today's Range

Now: $122.97

$121.37

$124.39

50 Day Range

MA: $118.89

$108.05

$127.74

2 Week Range

Now: $122.97

$99.06

$134.17

Volume

1,767,343 shs

Average Volume

675,822 shs

Market Capitalization

$7.43 billion

P/E Ratio

17.32

Dividend Yield

N/A

Beta

0.57

First JFK… next Elon?

From Porter & Company | Ad